Very hard to pick but here are my top 10 publications from 2024 which team ProsTIC contributed to: ① (Jan’24, Lancet Oncol) TheraP follow-up: Lu-177 PSMA-617 vs cabazitaxel in mCRPC ⇒ OS ~similar, better QoL. Ian Davis (Bluesky @profiand) ANZUP doi.org/10.1016/S1470-… ② (Feb’24, J

Congratulations to Michael Hofman and the ProsTIC team for their relentless efforts and outstanding contributions!🏆👏 #Oncology #Theranostics #CancerResearch Ian Davis (Bluesky @profiand) ANZUP Ben Tran Arun Azad

Michael Hofman (Michael Hofman )‘s top 10 publications from 2024 which ProsTic (ProsTIC) contributed to oncodaily.com/insight/211624 #Cancer #ProstateCancer #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology

Congrats Team ProsTIC ! A hyper-productive year. More to come in 2025 with results of VIOLET and AlphaBet clinical trials anticipated. James Buteau Louise Kostos

🎉 Thrilled to announce the promotion of Dr. Arun Azad to PROFESSOR Arun Azad A leader in uro-oncology, Professor Azad's groundbreaking work in prostate cancer has transformed care globally. Join us in congratulating him! 👏

Thanks to University of Melbourne for the Xmas present: promotion to Full Professor. Too many people to thank - my parents & brother, my wife Melissa Kaufman, many wonderful colleagues & collaborators, industry partners, & all the patients who have selflessly supported #ProstateCancer research 🙏

Ab#17 ASCO #GU25 by #LouiseEmmett👉bit.ly/4jVDXHR👉OS & HRQoL data from ENZA-p (ANZUP 1901) #prostatecancer👉Lu-177 + enza vs enza👉⬆️OS & HRQoL in poor risk mCRPC👇Martin Stockler OncoAlert UroToday.com PCF Science

Excited to have ANZUP #ENZAp #ProstateCancer #pcsm #ClinicalTrial OS and HRQoL data presented at #GU25 this week by the incomparable Louise Emmett - don’t miss it!

Devaki Surasi presents on combination trials with Lutetium-177 ... So many Aussie trials! ASCO #GU25 ProsTIC

We're back! Peter Mac Radiation Oncology Peter Mac Cancer Centre - Nov 14th and 15th.... save the date!!!! #radonc #radiotherapy

BREAKING NEWS🎉 Peter Mac Research researchers awarded $21M in NHMRC funding, including #prostic Director Michael Hofman! Prof. Hofman's research will incorporate new radioactive tumour seeking molecules, whole body scanning and AI for #prostatecancer clinical trials and treatments☢️

Michael Hofman presents at 2025 PSMA & Beyond Conference UCLA UC San Francisco Prostate Cancer Foundation ... Impressive attendance! Thanks to organisers: Thomas Hope Jeremie Calais Johannes Czernin UroToday.com Don't miss our next webinar: Link.prostic.org/webinar

Our webinars are back! Join us in Unravelling PSMA Biology on April 23/24 with Michael Hofman, PCF Science, GU Cast | Urology podcast! and our special guest speakers: Misha Beltran, Louise Emmett, Edmond Kwan & Martin Pomper, MD PhD 🔬 Live, interactive and FREE‼️ Register now: link.prostic.org/webinar

Huge congratulations to Michael Hofman for receiving the prestigious 2025 The Royal Australasian College of Physicians Eric Sussman Prize, presented for the best contribution to the knowledge of any branch of internal medicine, adult or pediatrics, for his work in prostate theranostics. racp.edu.au/news-and-event…

This week at Peter Mac Cancer Centre in the clinic: Therapy: Tb-161, Ac-225, Lu-177, Ra-223, I-131 Diagnostic: F-18, Ga-68, I-124, Tc-99m, Cr-51 Missing some our friends Zr-89, Cu-64, maybe next week ProsTIC

Clonal hematopoiesis (CH) in the ANZUP #TheraP study ASCO #ASCO25 presented by Asli Munzur ■ ¹⁷⁷Lu-PSMA-617: higher incidence of emergent CH compared to cabazitaxel chemotherapy ■ Most new clonal hematopoiesis mutations ¹⁷⁷Lu-PSMA-617 fall in DNA damage repair

Congrats @ANZUPTrials #TheraP study presented #ASCO25 by Dr Aslı Munzur. Thanks to Prostate Cancer Foundation BC Cancer Foundation Terry Fox Foundation #CanadianCancerSociety Peter Mac Cancer Centre ProsTIC Vancouver Prostate Centre VCH Research Institute University of British Columbia PCFA Movember Australia ANSTO @adacap_news NHMRC CTC The Distinguished Gentleman's Ride Novartis

#VIOLET Study of Terbium-161 (Tb-161) Beta/Auger therapy ASCO #ASCO25 First prospective trial of Terbium-161 in any tumour type 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣 Very few side effects: 1 grade 3

#ASCO25 BULSSEYE Ph2 trial👉 Lu-PSMA in oligo mHSPC ▶️58 pts oHSPC, PSA DT<6, max of 5 Mets 👉 R 1:1 Lu-PSMA vs. deferred ADT ▶️1 Endpoint: PFS (without ADT) ✨Rationale: Lu-PSMA as MDT monotherapy in oligorecurrent HSPC to prolong ADT-free interval👉HR 0.07 (0.02-0.19, p<0.001)

Dear Colleagues at #ASCO25 with an exciting day today in GU Oncology We invite you to read our paper Management of patients with Advanced #ProstateCancer : A Report from #APCCC24 LINK TO ARTICLE👇 sciencedirect.com/science/articl… The 2024 Advanced Prostate Cancer Consensus Conference